Global Diabetic Gastroparesis Treatment Market

Diabetic Gastroparesis Treatment Market size is expected to reach nearly USD 7.81 Bn. by 2032 with the CAGR of 5.9% during the forecast period.

Diabetic gastroparesis is delayed gastric emptying related to diabetes. The condition occurs in patients suffering from both type-1 and type-2 diabetes and is common in female patients suffering from type-2 diabetes. The disease includes delayed emptying of the stomach leading to a series of symptoms like nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heart burn.For example, according to the study, ‘Global Prevalence of Type-2 Diabetes over the forecast period (2026-2032), published by the American Diabetes Association, 500 million people worldwide suffered from type-2 diabetes in 2025.

To know about the Research Methodology :- Request Free Sample Report

Easy access to off-label medicines without instructions is expected to boost the growth of the diabetic gastroparesis market. Medications like anti-emetic drugs (oandesteron) are reasonable and easily accessible in developing economies. Also, increasing preference towards OTC medicines to avoid higher expenditures is leading to greater disbursement of drugs through retail pharmacies and drugstores.

Measures to support product approval and labeling claims for diabetic gastroparesis treatments are expected to offer profitable growth opportunities for a producer in the global diabetic gastroparesis treatment market. For instance, in Feb 2025, a team of researchers associated with Boston Therapeutics, Inc. stated that the Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to estimate treatment benefit in future diabetic gastroparesis interventional trials.

Initiatives of regulatory bodies to issue guidance for the development of drugs for the treatment of diabetic gastroparesis are also expected to support the growth of the diabetic gastroparesis treatment market. For example, in Aug 2025, the U.S. FDA issued guidance that reports FDA’s current references about clinical trial designs and clinical endpoint assessments to support the development of drugs for the treatment of idiopathic and diabetic gastroparesis.

The absence of clinical evidence on upgrading offered by prescription drugs is expected to hamperthe growth of the global diabetic gastroparesis treatment market. Metoclopramide, domperidone, and erythromycin are used for the treatment of diabetic gastroparesis. On the other hand, approvals of these drugs are inconsistent across countries, leading to the absence of accessibility of consistent patient progress data because ofthe administration of these drugs.

There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is mainly due to the early termination of clinical trials or the failure of drugs to meet statistically important endpoints. Such as, in Aug2018, Dartmouth-Hitchcock Medical Center terminated the randomized, double-blind, placebo-controlled trial of promethazine for treatment of diabetic gastroparesis, conducted in collaboration with the American College of Gastroenterology, because ofa shortage of recruitment.

Region-wise, the global diabetic gastroparesis treatment market has been segmented into Latin America, North America, Europe,Asia Pacific, the Middle East, and Africa. The diabetic gastroparesis treatment market in North America is expected to hold the largest market share of the total market in the future. This is mainly because of advancements in the diabetic care sector of the US.

Recent Industry Developments (2025–2026)

The objective of the report is to present a comprehensive analysis of the Global Diabetic Gastroparesis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SWOT, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Diabetic Gastroparesis Treatment Market dynamics, structure by analyzing the market segments and project the Global Diabetic Gastroparesis Treatment Market size. Clear representation of competitive analysis of key players By Therapeutics, price, financial position, product portfolio, growth strategies, and regional presence in the Global Diabetic Gastroparesis Treatment Market make the report investor’s guide.

Scope of the Global Diabetic Gastroparesis Treatment Market: Inquire before buying

Global Diabetic Gastroparesis Treatment Market, By Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key players/ competitors profile covered in brief in Diabetic Gastroparesis Treatment Market report in strategic perspective

1. Evoke Pharma
2. Allergan (AbbVie Inc.)
3. Bausch Health Companies Inc.
4. Johnson & Johnson Services, Inc.
5. Takeda Pharmaceutical Company Limited
6. AstraZeneca
7. Metacrine, Inc.
8. Vanda Pharmaceuticals Inc.
9. Theravance Biopharma
10. Cadila Pharmaceuticals
11. GlaxoSmithKline plc
12. Bristol-Myers Squibb Company
13. Eli Lilly and Company
14. Pfizer Inc.
15. Teva Pharmaceutical Industries Ltd.
16. Mylan N.V. (Viatris Inc.)
17. Novartis AG
18. Sanofi S.A.
19. Abbott Laboratories
20. Cinclus Pharma AG
21. Processa Pharmaceuticals, Inc.
22. Shionogi & Co., Ltd.
23. IPHARM
24. Neurogastrx, Inc.